Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Is The Androgen Deprivation Therapy Market Expected To Grow In Terms Of Size?
In recent times, the market size of androgen deprivation therapy has been on an upswing. Projections show robust growth from $7.81 billion in 2024 to $8.31 billion in 2025, with a compound annual growth rate (CAGR) of 6.3%. The historic growth can be credited to factors such as the global rise in prostate cancer incidence, an increasing number of aging males, a high recurrence rate of prostate cancer, improved long-term treatment survival rates, and enhanced awareness about the importance of early prostate cancer screening.
Anticipated to experience substantial growth in the ensuing years, the Androgen Deprivation Therapy market size is projected to expand to $10.49 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 6.0%. Factors contributing to this growth prediction include the widespread adoption of combination treatments in oncology, an escalating occurrence of hormone-sensitive cancers, increased instances of localized and advanced prostate cancer diagnosis, the extended application of ADT in non-oncological hormonal situations, and rising patient inclination towards non-invasive treatment modalities. Key trends for the forecast period include enhancements in depot formulations and delivery methods, the creation of oral ADT pharmaceuticals, the advent of long-acting ADT injectables, the presentation of novel androgen receptor inhibitors, and technological advancements in digital pathology and diagnostics.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp
What Are The Primary Factors Supporting The Androgen Deprivation Therapy Market Expansion?
The anticipated surge in prostate cancer cases is projected to stimulate the expansion of the androgen deprivation therapy market in future years. Originating from the prostate gland, a crucial part of the male reproductive system tasked with generating seminal fluid, prostate cancer incidence is uprising largely due to extended life expectancies since advanced age significantly escalates the likelihood of contracting the disease. Androgen Deprivation Therapy (ADT), designed to reduce androgen levels that propel tumor growth, is a fundamental treatment approach for prostate cancer. This is regularly employed during progressive or metastatic stages to hinder the advancement of the disease. For example, a report published by Prostate Cancer UK in January 2025 disclosed that the annual diagnosis of prostate cancer in England escalated from 50,751 cases in 2022 to 55,033 cases in 2023, demonstrating an evident annual upsurge. Consequently, the escalated incidence of prostate cancer facilitates the growth of the androgen deprivation therapy market.
Which Segmentation Categories Are Highlighted In The Androgen Deprivation Therapy Market Analysis?
The androgen deprivation therapy market covered in this report is segmented –
1) By Type: Medicine, Surgery, Other Types
2) By Route Of Administration: Injectable, Oral
3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75
4) By Application: Prostate Cancer, Other Applications
5) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies
2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy
3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU
Which Market Trends Are Expected To Define The Future Of The Androgen Deprivation Therapy Market?
Key firms involved in the androgen deprivation therapy market are prioritizing the development of innovative solutions such as combination therapies to enhance treatment results in advanced prostate cancer. Combination therapies employ more than one kind of therapy like hormone treatment and chemotherapy to boost therapeutic efficacy and stall the progression of the illness. For example, in August 2022, Bayer AG, a company specializing in life sciences based in Germany, was granted approval by the U.S Food and Drug Administration for the additional use of darolutamide in conjunction with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). This newly approved combination therapy aims to improve the survival rates and slow down disease progression in patients with mHSPC – a stage where the cancer has spread but remains responsive to hormone treatment. One noteworthy feature of this treatment is the use of darolutamide – a pill that targets androgen receptors. It attaches tightly to these receptors due to its distinctive molecular structure. This effectively blocks the activity of these receptors, contributing to the prevention of the growth and spread of prostate cancer cells.
Which Organizations Are At The Forefront Of The Androgen Deprivation Therapy Market?
Major companies operating in the androgen deprivation therapy market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Astellas Pharma Inc., Ipsen S.A., Dr. Reddy’s Laboratories Ltd., Orion Corporation, Arvinas Inc., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Verity Pharmaceuticals Inc., Lawley Pharmaceuticals Pty Ltd.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Androgen Deprivation Therapy Market?
North America was the largest region in the androgen deprivation therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp
Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2025, By The Business Research Company
Androgenetic Alopecia Treatment Global Market Report 2025
Testosterone Booster Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/testosterone-booster-global-market-report
Synthetic Hormones Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/synthetic-hormones-global-market-report
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
